Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Common Stock: ¥453 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600566 Hubei Jumpcan Pharmaceutical Co Ltd SHSE:600566
81 GF Score
Price ¥26.38
GF Value ¥21.08
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hubei Jumpcan Pharmaceutical Co Common Stock?

Hubei Jumpcan Pharmaceutical Co SHSE:600566 -1.75% 81 Common Stock is ¥453 Mil as of Mar. 2026. GuruFocus rates SHSE:600566 with a GF Score™ of 81/100 and a GF Value™ of ¥21.08 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Hubei Jumpcan Pharmaceutical Co's quarterly common stock increased from Sep. 2025 (¥452 Mil) to Dec. 2025 (¥453 Mil) and increased from Dec. 2025 (¥453 Mil) to Mar. 2026 (¥453 Mil).

Hubei Jumpcan Pharmaceutical Co's annual common stock declined from Dec. 2023 (¥453 Mil) to Dec. 2024 (¥453 Mil) and declined from Dec. 2024 (¥453 Mil) to Dec. 2025 (¥453 Mil).

Hubei Jumpcan Pharmaceutical Co Common Stock Historical Data

* Premium members only.

The historical data trend for Hubei Jumpcan Pharmaceutical Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hubei Jumpcan Pharmaceutical Co Common Stock Chart

Hubei Jumpcan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 436.27 452.74 452.74 452.69 452.51

Hubei Jumpcan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 452.69 452.69 452.17 452.51 452.67
SHSE:600566
81GF Score
Hubei Jumpcan Pharmaceutical Co Ltd SHSE:600566
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hubei Jumpcan Pharmaceutical Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ¥453 Mil mean?
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) has a Common Stock of ¥453 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors.
Is Hubei Jumpcan Pharmaceutical Co's Common Stock too high?
Hubei Jumpcan Pharmaceutical Co's current Common Stock is ¥453 Mil. Overall, Hubei Jumpcan Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hubei Jumpcan Pharmaceutical Co's Common Stock compare to ZTS?
Hubei Jumpcan Pharmaceutical Co's Common Stock of ¥453 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. Hubei Jumpcan Pharmaceutical Co's current Common Stock is ¥453 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Jumpcan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co (SHSE:600566) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥21.08, compared to a current price of ¥26.38 — trading 25.1% above its estimated fair value. The current Common Stock is ¥453 Mil. Hubei Jumpcan Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Hubei Jumpcan Pharmaceutical Co (SHSE:600566), the current Common Stock is ¥453 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Overvalued in 2026?

Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥26.38 is trading 25.1% above its estimated GF Value™ of ¥21.08. GuruFocus considers Hubei Jumpcan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600566:

  • Common Stock: ¥453 Mil
  • GF Value™: ¥21.08 vs. price of ¥26.38 (25.1% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hubei Jumpcan Pharmaceutical Co Business Description

Address Daqing West Road, Baota Bay, Jiangsu Province, Taixing, CHN, 225441
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
81GF Score

Get the complete analysis for SHSE:600566

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.38
Price
¥21.08
GF Value